JAMA·· 5 hours agoPickScore94
Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial.
In brief
The phase 3 HORIZON-Breast06 trial showed that trastuzumab rezetecan (SHR-A1811) significantly prolonged progression-free survival compared with chemotherapy in patients with ERBB2-low advanced breast cancer.
Why it matters
HORIZON-Breast06 reports PFS, key subgroup and adverse event data within one randomized controlled framework, enabling comparison of SHR-A1811 with chemotherapy.
Source: JAMA · doi.org